Clients News • MC Services corporate website
5522
page-template-default,page,page-id-5522,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

CLIENT NEWS

 

 

  • Destiny Pharma: Notice of R&D Update Meeting
    22 September 2022
    www.destinypharma.com
  • Spexis announces positive renal impairment clinical trial results with balixafortide
    22 September 2022
    www.spexisbio.com
  • CEVEC: ROKOTE Laboratories licenses CEVEC’s CAP® Ad Technology for vaccine manufacturing
    20 September 2022
    www.cevec.com
  • Atriva Therapeutics announces Topline Results from the Proof of Concept (POC) / Phase 2a RESPIRE study (zapnometinib) in patients hospitalized with COVID-19
    20 September 2022
    www.atriva-therapeutics.com
  • ABIVAX PRESENTS FIRST-HALF 2022 FINANCIAL RESULTS AND OPERATIONS UPDATE
    16 September 2022
    www.abivax.com
  • Newron provides H1 2022 results and updates on R&D and business activities
    15 September 2022
    www.newron.com
  • Marinomed to attend several upcoming investor and industry conferences
    13 September 2022
    www.marinomed.com
  • HeartBeat.bio and Molecular Devices announce collaboration to automate and scale cardiac organoids for high-throughput screening in drug discovery
    12 September 2022
    www.heartbeat.bio
  • InflaRx to Present at Upcoming Scientific and Investor Conferences
    09 September 2022
    www.inflarx.de
  • InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
    08 September 2022
    www.inflarx.de